These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16988392)

  • 1. A pharmaceutical company user's perspective on the potential of high content screening in drug discovery.
    Hoffman AF; Garippa RJ
    Methods Mol Biol; 2007; 356():19-31. PubMed ID: 16988392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High content screening as a screening tool in drug discovery.
    Nichols A
    Methods Mol Biol; 2007; 356():379-87. PubMed ID: 16988417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
    Donato MT; Gómez-Lechón MJ; Tolosa L
    Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in high content screening for drug discovery.
    Giuliano KA; Haskins JR; Taylor DL
    Assay Drug Dev Technol; 2003 Aug; 1(4):565-77. PubMed ID: 15090253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirements, features, and performance of high content screening platforms.
    Gough AH; Johnston PA
    Methods Mol Biol; 2007; 356():41-61. PubMed ID: 16988394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CellProfiler and KNIME: Open-Source Tools for High-Content Screening.
    Stöter M; Janosch A; Barsacchi R; Bickle M
    Methods Mol Biol; 2019; 1953():43-60. PubMed ID: 30912015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of high-content screening (HCS) technology and its importance to drug discovery.
    Fraietta I; Gasparri F
    Expert Opin Drug Discov; 2016; 11(5):501-14. PubMed ID: 26971542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the integration of immunoreagents and fluorescent probes for multiplexed high content screening assays.
    Giuliano KA
    Methods Mol Biol; 2007; 356():189-93. PubMed ID: 16988403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Past, present, and future of high content screening and the field of cellomics.
    Taylor DL
    Methods Mol Biol; 2007; 356():3-18. PubMed ID: 16988391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening for analysis of in vitro toxicity.
    Schoonen WG; Westerink WM; Horbach GJ
    EXS; 2009; 99():401-52. PubMed ID: 19157069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCS-Analyzer: open source software for high-content screening data correction and analysis.
    Ogier A; Dorval T
    Bioinformatics; 2012 Jul; 28(14):1945-6. PubMed ID: 22586178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G-protein coupled receptor assays: to measure affinity or efficacy that is the question.
    Williams C; Sewing A
    Comb Chem High Throughput Screen; 2005 Jun; 8(4):285-92. PubMed ID: 16101004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A personal perspective on high-content screening (HCS): from the beginning.
    Taylor DL
    J Biomol Screen; 2010 Aug; 15(7):720-5. PubMed ID: 20639498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of informatics for high content screening.
    Dunlay RT; Czekalski WJ; Collins MA
    Methods Mol Biol; 2007; 356():269-80. PubMed ID: 16988410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations.
    Rishton GM
    Med Chem; 2005 Sep; 1(5):519-27. PubMed ID: 16787336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Based Assay Design for High-Content Screening of Drug Candidates.
    Nierode G; Kwon PS; Dordick JS; Kwon SJ
    J Microbiol Biotechnol; 2016 Feb; 26(2):213-25. PubMed ID: 26428732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation.
    Haney SA
    Expert Opin Drug Discov; 2006 Jun; 1(1):19-29. PubMed ID: 23506030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening: update on practices and success.
    Fox S; Farr-Jones S; Sopchak L; Boggs A; Nicely HW; Khoury R; Biros M
    J Biomol Screen; 2006 Oct; 11(7):864-9. PubMed ID: 16973922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-content screening in microfluidic devices.
    Cheong R; Paliwal S; Levchenko A
    Expert Opin Drug Discov; 2010 Aug; 5(8):715-20. PubMed ID: 21852997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.